Cargando…
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M or other acquired mutations are sensitive to the Aurora B (AURKB) inhibitors barasertib and S49...
Autores principales: | Bertran-Alamillo, Jordi, Cattan, Valérie, Schoumacher, Marie, Codony-Servat, Jordi, Giménez-Capitán, Ana, Cantero, Frédérique, Burbridge, Mike, Rodríguez, Sonia, Teixidó, Cristina, Roman, Ruth, Castellví, Josep, García-Román, Silvia, Codony-Servat, Carles, Viteri, Santiago, Cardona, Andrés-Felipe, Karachaliou, Niki, Rosell, Rafael, Molina-Vila, Miguel-Angel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472415/ https://www.ncbi.nlm.nih.gov/pubmed/31000705 http://dx.doi.org/10.1038/s41467-019-09734-5 |
Ejemplares similares
-
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
por: Jacobsen, Kirstine, et al.
Publicado: (2017) -
Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells
por: Codony-Servat, Jordi, et al.
Publicado: (2020) -
STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2018) -
Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019) -
Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)
por: Codony-Servat, Carles, et al.
Publicado: (2017)